CDH1 and cancer: In an era of high-throughput genome sequencing and multiplex gene panel testing, this problem is becoming unwieldy with the identification of an increasing number of variants of unknown significance (VUS), not only in disease but also in individuals without family history of gastric cancer [24,25] This, along with the fact that the majority of cancer screening programs do not recommend CDH1 testing in the absence of specific clinical criteria, urges the need to streamline CDH1 screening.